摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯-3,6-二氟苯酚 | 261762-50-9

中文名称
2-氯-3,6-二氟苯酚
中文别名
1-(5-甲基-2-哌啶基)哌嗪
英文名称
2-chloro-3,6-difluorophenol
英文别名
2-chloro-3,6-fluorophenol
2-氯-3,6-二氟苯酚化学式
CAS
261762-50-9
化学式
C6H3ClF2O
mdl
MFCD01631450
分子量
164.539
InChiKey
IXIZSAAJTPZUBU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    52-56°C
  • 沸点:
    171.7±35.0 °C(Predicted)
  • 密度:
    1.520±0.06 g/cm3(Predicted)
  • 稳定性/保质期:
    避氧化物

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险等级:
    TOXIC
  • 危险等级:
    8
  • 危险品标志:
    Xn,Xi,T
  • 安全说明:
    S26,S36/37,S36/37/39,S39,S9
  • 危险类别码:
    R20/21/22
  • 海关编码:
    2908199090
  • 包装等级:
    III
  • 危险标志:
    GHS05,GHS07
  • 危险品运输编号:
    UN 2811
  • 危险性描述:
    H302,H315,H318,H335
  • 危险性防范说明:
    P261,P280,P305 + P351 + P338

SDS

SDS:d0ddc71f5e70f7dc5130d8f64c284f78
查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-Chloro-3,6-difluorophenol
: Fluka
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 261762-50-9


SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Skin irritation (Category 2), H315
Serious eye damage (Category 1), H318
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22, R37/38, R41
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
Harmful if swallowed.
Causes skin irritation.
Causes serious eye damage.
May cause respiratory irritation.
Precautionary statement(s)
Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
Wear protective gloves/ eye protection/ face protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

SECTION 3: Composition/information on ingredients
Substances
Formula : C6H3ClF2O
Molecular Weight : 164,54 g/mol
CAS-No. : 261762-50-9
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2-Chloro-3,6-difluorophenol
CAS-No. 261762-50-9 Acute Tox. 4; Skin Irrit. 2; Eye <= 100 %
Dam. 1; STOT SE 3; H302,
H315, H318, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2-Chloro-3,6-difluorophenol
CAS-No. 261762-50-9 Xn, R22 - R37/38 - R41 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
anticipated use by our customers. It should not be construed as offering an approval for any
specific use scenario.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,6
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    2-氯-3,6-二氟苯酚sodium hydroxide三丁基膦1,1'-azodicarbonyl-dipiperidine 作用下, 以 甲苯 为溶剂, 反应 3.5h, 生成 8-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5-aza-spiro[2.5]oct-7-ene-5,7-dicarboxylic acid 5-tert-butyl ester
    参考文献:
    名称:
    [EN] TETRAHYDROPYRIDINE DERIVATIVES
    [FR] DERIVES DE TETRAHYDROPYRIDINE
    摘要:
    本发明涉及新型的四氢吡啶衍生物及其作为活性成分用于制备药物组合物中的应用。本发明还涉及相关方面,包括制备这些化合物的方法、含有一种或多种这些化合物的药物组合物,尤其是它们作为肾素抑制剂的应用。其中,X和Y分别独立地代表氢、氟或甲基;X和Y不同时代表氢,或者X和Y可以共同形成一个环丙基环;W代表苯基或杂芳基,杂芳基环是一个六元非融合环,苯基环和杂芳基在3或4位置被V取代;A和B独立地代表- O-;-S-;-SO-或-SO2-;U代表芳基或杂芳基;T代表-CONR1-;-(CH2)pOCO-;-(CH2)pN(R1)CO-;-(CH2)pN(R1)SO2-;-COO-;-(CH2)pOCONR1-或-(CH2)pN(R2)CONR1-;R1和R2分别独立地代表氢;低级烷基;低级烯基;低级炔基;环烷基;芳基低级烷基,杂芳基低级烷基或环烷基低级烷基;Q代表低级烷基或低级烯基;M代表氢;环烷基;芳基;杂环基或杂芳基:
    公开号:
    WO2005040120A1
点击查看最新优质反应信息

文献信息

  • Primary Amines as Renin Inhibitors
    申请人:Bezencon Olivier
    公开号:US20090088457A1
    公开(公告)日:2009-04-02
    The invention relates to novel primary amine derivatives and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.
    这项发明涉及新型一次胺衍生物及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面,包括制备这些化合物的过程、含有其中一种或多种化合物的药物组合物,特别是它们作为肾素抑制剂的用途。
  • Secondary Amines as Renin Inhibitors
    申请人:Bezencon Olivier
    公开号:US20090176823A1
    公开(公告)日:2009-07-09
    The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.
    这项发明涉及公式(I)的新型二级胺衍生物及其作为药物组成物中的活性成分的用途。该发明还涉及相关方面,包括制备这些化合物的过程、含有其中一个或多个这些化合物的药物组成物,特别是它们作为肾素抑制剂的用途。
  • Novel Piperidine Carboxylic Acid Amide Derivatives
    申请人:Bezencon Olivier
    公开号:US20080214598A1
    公开(公告)日:2008-09-04
    The invention relates to novel piperidine carboxylic acid amide derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of these novel compounds, pharmaceutical compositions comprising such compounds and especially the use of such compounds as inhibitors of renin.
    本发明涉及新型的哌啶羧酸酰胺衍生物及其作为活性成分用于制备药物组合物。本发明还涉及相关方面,包括这些新型化合物的制备方法、包含此类化合物的药物组合物,尤其是此类化合物作为肾素抑制剂的应用。
  • Design and Preparation of Potent, Nonpeptidic, Bioavailable Renin Inhibitors
    作者:Olivier Bezençon、Daniel Bur、Thomas Weller、Sylvia Richard-Bildstein、Luboš Remeň、Thierry Sifferlen、Olivier Corminboeuf、Corinna Grisostomi、Christoph Boss、Lars Prade、Stéphane Delahaye、Alexander Treiber、Panja Strickner、Christoph Binkert、Patrick Hess、Beat Steiner、Walter Fischli
    DOI:10.1021/jm900022f
    日期:2009.6.25
    Starting from known piperidine renin inhibitors, a new series of 3,9-diazabicyclo[3.3.1]nonene derivatives was rationally designed and prepared. Optimization of the positions 3, 6, and 7 of the diazabicyclonene template led to potent renin inhibitors. The substituents attached at the positions 6 and 7 were essential for the binding affinity of these compounds for renin. The introduction of a substituent
    从已知的哌啶肾素抑制剂开始,合理设计和制备了一系列新的3,9-二氮杂双环[3.3.1]壬烯衍生物。优化二氮杂双环烯模板的位置3、6和7导致有效的肾素抑制剂。在6和7位上连接的取代基对于这些化合物对肾素的结合亲和力是必不可少的。引入在3位上连接的取代基不会改变结合亲和力,但可以调节ADME性质。我们的努力导致发现抑制肾素的化合物(+)- 26g,在缓冲液中的IC 50为0.20 nM,在血浆中的IC 50为19 nM。讨论了该化合物和其他类似化合物的药代动力学特性。化合物(+)- 26克 在大鼠中被很好地吸收,在体内10 mg / kg时有效。
  • [EN] DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS<br/>[FR] DERIVES DE DIAZABICYCLONONENE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA RENINE
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2005040165A1
    公开(公告)日:2005-05-06
    The invention relates to novel derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.
    本发明涉及新颖衍生物及相关化合物,以及它们作为活性成分用于制备药物组合物的用途。本发明还涉及相关方面,包括制备这些化合物的方法、含有一种或多种这些化合物的药物组合物,尤其是它们作为肾素抑制剂的使用。
查看更多